Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride helps improve treatment for benign prostatic hyperplasia.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

Terazosin hydrochloride helps with BPH and blood pressure, but not more than the control.

Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

Resveratrol shows health benefits but faces challenges in effectiveness and regulation.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Saw palmetto supplements may reduce prostate cancer cell growth without being toxic.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Male pattern baldness may predict prostate cancer risk.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

New steroids were effective in blocking male hormone receptors in hamster prostates.

Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.